Dana-Farber Cancer Institute | Strategic Alliance Partners

April 27, 2023

Bradley A. McGregor, MD, discusses the clinical significance of the updated COSMIC-021 data, how these findings support the continued investigation of IO/TKI combinations in non–clear cell renal cell carcinoma, and other efforts underway to better care for patients with varying histological subtypes of the disease.

April 25, 2023

Ursula A. Matulonis highlights previous data from the phase 3 ENGOT-OV16/NOVA trial initial readout and subsequent preplanned overall survival analysis, discusses new findings from the final analysis, and emphasizes how these data clarify some of the study’s limitations and reinforce the importance of adhering to the adjusted FDA label for niraparib in recurrent ovarian cancer.

April 17, 2023

In a new study in the journal Nature Cancer, Dana-Farber Cancer Institute scientists shed new light on the mechanism that raises and lowers PSMA expression in prostate cancer cells.

April 14, 2023

Bradley McGregor, MD, discusses the next steps for investigating cabozantinib plus atezolizumab in patients with advanced renal cell carcinoma.

April 14, 2023

Investigators of an ongoing phase 1a/1b multicohort trial are studying whether addition of adaptive immune activators increases the benefit derived from anti–PD-1 antibodies in multiple tumor types.

April 13, 2023

Christopher Lathan, MD, MS, MPH, discusses socioeconomical and clinical findings from a clinical outreach program incorporating cancer diagnostic services and patient navigation for patients from traditionally underserved populations.

April 10, 2023

Presenters from the 2023 SGO Annual Meeting share their insights on the treatment of patients with gynecologic cancers.

April 05, 2023

Research from Dana-Farber Cancer Institute looks at what happens before the emergence of mutations that interrupt cellular differentiation in colorectal cancer and finds not only evidence of fetal reprogramming that can initiate cancer, but also a protein, Sox9, that fuels that reprogramming.

April 04, 2023

Adagrasib induced high overall response rates in patients with KRAS G12C–mutated non–small cell lung cancer who achieved at least 90% mutation allele frequency clearance.

March 31, 2023

As the first clinical trial of the drug novobiocin is about to open for patients with cancers carrying BRCA gene mutations, new research at Dana-Farber Cancer Institute shows the drug poses a double threat to tumor cells.

March 30, 2023

Ursula A. Matulonis, MD, discusses common toxicities associated with mirvetuximab soravtansine-gynx, and how to properly manage these treatment-related adverse effects for patients with folate receptor alpha-high ovarian cancer.

March 29, 2023

Dana-Farber Cancer Institute researchers outline the complexities of colorectal cancer and the research needed to map out a path toward understanding it.

March 27, 2023

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

March 20, 2023

Dr Tolaney discusses the FDA approval of sacituzumab govitecan in patients with unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer; key data from the TROPiCS-02 trial; and how this agent can fulfill unmet needs for this patient population.

March 17, 2023

Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.

March 14, 2023

Paul G. Richardson, MD, discusses the impact of combining proteasome inhibitors and monoclonal antibodies in multiple myeloma.

March 13, 2023

Despite a perhaps overwhelming number of combination regimens available for use in the frontline setting for patients with renal cell carcinoma, treatment decisions can still largely boil down to a patient’s risk status. For second-line therapy, investigators are looking to contemporary trials for guidance.

March 10, 2023

Given the current lack of positive phase 3 immunotherapy trials for glioblastoma, a misconception held by oncologists and neuro-oncologists is that immunotherapy has no place in this malignancy.

March 09, 2023

The progression-free survival benefit associated with the combination of nivolumab plus cabozantinib compared with sunitinib was largely independent of PD-L1 and c-MET status in previously untreated patients with advanced or metastatic renal cell carcinoma.

March 07, 2023

The advent of effective first-generation TKIs has allowed for improvements among patients with Philadelphia chromosome–positive disease, which is traditionally associated with a poor prognosis, as it generally does not respond to conventional chemotherapy options.